Drug Trial Radar · NCT05671835
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
May 15, 2023
Primary completion
Aug 14, 2025
Study completion Aug 14, 2025
Sponsor
- Lead sponsor
- Tvardi Therapeutics, IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jan 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
TTI-101Drug
Orally via a tablet.
PlaceboDrug
Orally via a tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with an Adverse Event (AE)Time frame: 16 weeks
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
The Kirklin Clinic of University of Alabama Birmingham Hospital
Birmingham, Alabama
University of California San Diego
La Jolla, California
University of California Irvine (UCI) Health
Orange, California
University of Colorado School of Medicine
Aurora, Colorado
Saint Francis Sleep Allergy and Lung Institute
Clearwater, Florida
University of Florida
Gainesville, Florida
UHealth - University of Miami Health Systems
Miami, Florida
Emory University Hospital
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Chicago Medicine
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Tulane University School of Medicine
New Orleans, Louisiana
The Lung Research Center
Chesterfield, Missouri
New York University Langone Pulmonary and Critical Care Associates
Brooklyn, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Pulmonix
Greensboro, North Carolina
Salem Chest Specialists
Winston-Salem, North Carolina
Saint Luke's University Hospital - Bethlehem
Bethlehem, Pennsylvania
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
The Medical University of South Carolina
Charleston, South Carolina
Clinical Trials Center of Middle Tennessee
Franklin, Tennessee
Baylor Scott & White Center for Advanced Heart & Lung Disease
Dallas, Texas
Baylor College of Medicine
Houston, Texas
University of Texas Health Science Center at Houston (UT Health)
Houston, Texas
Metroplex Pulmonary and Sleep Center
McKinney, Texas
Inova Fairfax Medical Campus
Falls Church, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.